A Literature Review of Active A?-Immunotherapy with CAD106 for Alzheimer's Disease

Mohit Upadhye; Dr Ivan Netto

Volume : VII, Issue : VIII, August - 2018

A Literature Review of Active A?-Immunotherapy with CAD106 for Alzheimer's Disease

Mohit Upadhye, Dr Ivan Netto

Abstract :

Background:CAD106 is a second generation immunotherapeutic agent developed for the treatment of Alzheimer’s disease. It induces an antibody response against Aβ–peptides in the ains of Alzheimer patients and has been found to be safer than the former vaccine formulations in animal models. The review assesses the safety, tolerability and immunogenicity of CAD106 in the treatment of Alzheimer’s disease. Materials and methods: An electronic search was done on ‘PubMed’ using the keywords “CAD106”, “Alzheimer’s disease”, “immunotherapy AND Alzheimer’s disease”. Three randomized placebo–controlled trials were studied for the review. Results: The three trials reported mild to moderate adverse events with the use of CAD106. The vaccine induced an acceptable serologic response without evoking an autoimmune response or causing T–cell activation. It reduced the ain–amyloid load in strong serologic responders. However, no treatment–related benefits were seen. Conclusion: CAD106 is safe, tolerable and immunogenic with uncertain treatment–related benefits.